<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02399462</url>
  </required_header>
  <id_info>
    <org_study_id>15-0999</org_study_id>
    <secondary_id>ACTH-101</secondary_id>
    <nct_id>NCT02399462</nct_id>
  </id_info>
  <brief_title>Acthar for Treatment of Post-transplant FSGS</brief_title>
  <official_title>Acthar for Treatment of Post-transplant FSGS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label safety and feasibility trial using Acthar® in addition to&#xD;
      center-specific standard therapy including plasma exchange, for treatment of post transplant&#xD;
      recurrent FSGS and post transplant recurrent idiopathic membranous nephropathy. Subjects will&#xD;
      receive Acthar® 40 units subcutaneously (SC) twice weekly for two weeks then 80 units SC&#xD;
      twice weekly for 24 weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Funding terminated prematurely&#xD;
  </why_stopped>
  <start_date type="Anticipated">March 2021</start_date>
  <completion_date type="Actual">July 31, 2021</completion_date>
  <primary_completion_date type="Actual">July 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of patients with proteinuria</measure>
    <time_frame>24 and 52 weeks</time_frame>
    <description>partial and complete remission of proteinuria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Graft loss</measure>
    <time_frame>during study period</time_frame>
    <description>graft loss defined by return to dialysis, re-transplant or death during study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>eGFR change</measure>
    <time_frame>weeks 4,8,12,16,20 and 24</time_frame>
    <description>estimated Glomerular filtration rate (eGFR MDRD formula) change from baseline</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>FSGS</condition>
  <condition>Renal Transplantation</condition>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>Study Drug Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acthar SC injections</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acthar</intervention_name>
    <description>Agent Dose Route Schedule H.P. Acthar Gel 40 units SC twice weekly* Weeks 1 and 2&#xD;
H.P. Acthar Gel 80 units SC twice weekly* Weeks 3 through 24&#xD;
H.P. Acthar Gel 80 units SC once weekly* Weeks 25 through 26&#xD;
H.P. Acthar Gel 40 units SC once weekly* Weeks 27 through 28&#xD;
*Injections are to be spaced 72-96 hours apart (+/-6 hours).</description>
    <arm_group_label>Study Drug Arm</arm_group_label>
    <other_name>ACTH (adrenocorticotropic hormone ), corticotropin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Proteinuria &gt; 1 g/d by urine protein/creatinine ratio (UP/C) or 24 hour urine&#xD;
             collection&#xD;
&#xD;
          -  If treated with an angiotensin-converting-enzyme inhibitor (ACEi) or Angiotensin II&#xD;
             receptor blockers (ARB), must be on a stable dose for at least 2 weeks prior to&#xD;
             enrollment&#xD;
&#xD;
          -  Newly diagnosed recurrent focal and segmental glomerulosclerosis (FSGS), or&#xD;
             current/previous treatment of recurrent FSGS with no evidence of at least a partial&#xD;
             response as defined by one or more of the following:&#xD;
&#xD;
               1. Recurrent FSGS confirmed by renal transplant biopsy (FSGS on light microscopy&#xD;
                  and/or foot process effacement on electron microscopy), with FSGS as the primary&#xD;
                  disease confirmed by native renal biopsy prior to transplant&#xD;
&#xD;
               2. FSGS confirmed by renal transplant biopsy (FSGS on light microscopy and/or foot&#xD;
                  process effacement on electron microscopy), within 18 months post transplant&#xD;
&#xD;
               3. Patients at any time period post transplant with an established diagnosis of&#xD;
                  recurrent FSGS in the first 18 months post transplant who did not respond to&#xD;
                  conventional therapy as defined by persistent proteinuria of &gt; 3 g/d by UP/C or&#xD;
                  24 hour urine collection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lactation, pregnancy or refusal of birth control in women of childbearing potential&#xD;
&#xD;
          -  Infection with human immunodeficiency virus (HIV), hepatitis B, hepatitis C, or&#xD;
             parvovirus B-19&#xD;
&#xD;
          -  Malignancy (with the exception of treated and cured basal cell or squamous cell&#xD;
             carcinoma)&#xD;
&#xD;
          -  Evidence of diabetic nephropathy, transplant glomerulopathy or other pathologies that&#xD;
             could be associated with secondary FSGS on renal transplant biopsy&#xD;
&#xD;
          -  Non-renal organ transplant (with the exception of pancreas transplant)&#xD;
&#xD;
          -  Contraindication to receiving Acthar®&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karin True, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 8, 2015</study_first_submitted>
  <study_first_submitted_qc>March 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2015</study_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenocorticotropic Hormone</mesh_term>
    <mesh_term>Melanocyte-Stimulating Hormones</mesh_term>
    <mesh_term>beta-Endorphin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

